Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for depression after PCI or CABG in cardiac patients
IRCT20090117001556N154Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Cilostazol with Placebo (2 arms). Primary endpoint: Depression severity. Started Dec 2023; status: completed.
02
Drugs
cilostazol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N154.